Topics

NICE issues draft guidance rejecting Merck & Co.'s Keytruda in first-line head and neck cancer http://www.firstwordpharma.com/node/1693841?tsid=28®ion_id=6 …

10:33 EST 15 Jan 2020 | FirstWord Pharma

NICE issues draft guidance rejecting Merck & Co.'s Keytruda in first-line head and neck cancer http://www.firstwordpharma.com/node/1693841?tsid=28&region_id=6 …

Original Article: NICE issues draft guidance rejecting Merck & Co.'s Keytruda in first-line head and neck cancer http://www.firstwordpharma.com/node/1693841?tsid=28®ion_id=6 …

NEXT ARTICLE

More From BioPortfolio on "NICE issues draft guidance rejecting Merck & Co.'s Keytruda in first-line head and neck cancer http://www.firstwordpharma.com/node/1693841?tsid=28®ion_id=6 …"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...